Agree ! https://www.innovamedgroup.com/covidlyt
Post# of 22467
(Total Views: 342)
Posted On: 11/08/2020 5:28:24 PM
Agree !
https://www.innovamedgroup.com/covidlytics
INNOVA Medical Group COVIDLytics™ - Real-Time Data and Predictive Analytics Quantifying
COVID-19 Risk on an Individual & Environmental Basis
COVIDLytics™ Overview
Quantifies COVID-19 risk on an individual and environmental basis
Real-time data and predictive analytics impart improved public health decisions and outcomes
Open architecture adapts to different protocols
Allows data can be combined with existing data in any testing environment
Speeds the integration of testing and tracing data systems
Reduces burdens on research teams when proprietary software will not replicate in other environments
Identifies high-risk groups, then alert hospitals, nursing homes, and schools to redirect limited supply chain resources
Data-driven testing protocols highlight whom to test and with what frequency
These factors, combined with digitally-based contact tracing, can contain the spread of the SARS-CoV-2 virus
With COVID-19 global outbreaks expected during the fall and winter, Innova Medical Group understands that until a vaccine is available, widespread testing and tracing can flatten the curve and help avoid economic shutdowns. Global researchers believe actual cases could be ten times higher than reported cases. The Centers for Disease Control and Prevention (CDC) reports that up to 40 percent of infected people are asymptomatic. This bleak outlook is combined with a lack of clarity on how this season’s flu respiratory virus could interact and have overlapping symptoms with COVID-19.
Most people will not self-quarantine until COVID-19 symptoms become severe. This testing lag can lead to rapid spread as the most infectious period for this highly contagious virus is two days before and after symptoms. Mass testing at point-of-care, such as walk-in, drive-through, and mobile testing facilities, can provide early detection and contain outbreaks. The low cost, safe INNOVA Rapid SARS-CoV-2 Antigen Test can screen asymptomatic individuals with 98.98% accuracy. The IMG test, which incorporates an advanced, nitrocellulose membrane, makes it one of the most advanced in the world. In vitro diagnostic (IVD), nasal, throat, and cheek swabs, are safely gathered and combined with a testing reagent. In as little as 20 minutes, a negative result provides peace of mind, while a positive result ensures one can quarantine and not spread the disease at school or a workplace.
With its encrypted blockchain security, the QDX HealthID™ Smartphone App tracks and reports test results privately. The app (available on iPhone and Android devices) collects a person’s name, email address, phone number, zip code, and test results. This easy-to-use digital “health passport” lets people share information only to those who need to know. A user’s authenticated status will be displayed with a green, yellow, or red badge. Its cloud-based technology, Auth0 integration, and capture of QR codes complies with HIPAA and HL7 requirements. The QDX HealthID™ Smartphone App will never share privacy data.
Not only can COVIDLytics™’ customizable set of rules quantify risk on an individual basis, but also the risk to a specific environment. Community profiles can be generated to let local, state, and country government officials better target interventions. Its real-time data and predictive analytics will impart improved public health decisions and outcomes.
Misinformation has real-world consequences. Already, many communities face crowded hospitals and cost pressures. The mass amounts of data, collected through widespread testing, can be shared for research purposes and better case tracking of potential disease outbreaks.
COVIDLytics™’ open architecture adapts to different protocols so its data can be combined with data already collected in any existing testing environment. This speeds the integration of testing and tracing data systems and reduces the burden to research teams when proprietary software will not replicate in other environments. The use of COVIDLytics™ can identify high-risk groups, then alert hospitals, nursing homes, and schools to redirect their limited supply chain resources. Data-driven protocols will highlight whom to test and with what frequency. These factors, combined with digitally-based contact tracing, can contain the spread of the SARS-CoV-2 virus.
https://www.innovamedgroup.com/covidlytics
INNOVA Medical Group COVIDLytics™ - Real-Time Data and Predictive Analytics Quantifying
COVID-19 Risk on an Individual & Environmental Basis
COVIDLytics™ Overview
Quantifies COVID-19 risk on an individual and environmental basis
Real-time data and predictive analytics impart improved public health decisions and outcomes
Open architecture adapts to different protocols
Allows data can be combined with existing data in any testing environment
Speeds the integration of testing and tracing data systems
Reduces burdens on research teams when proprietary software will not replicate in other environments
Identifies high-risk groups, then alert hospitals, nursing homes, and schools to redirect limited supply chain resources
Data-driven testing protocols highlight whom to test and with what frequency
These factors, combined with digitally-based contact tracing, can contain the spread of the SARS-CoV-2 virus
With COVID-19 global outbreaks expected during the fall and winter, Innova Medical Group understands that until a vaccine is available, widespread testing and tracing can flatten the curve and help avoid economic shutdowns. Global researchers believe actual cases could be ten times higher than reported cases. The Centers for Disease Control and Prevention (CDC) reports that up to 40 percent of infected people are asymptomatic. This bleak outlook is combined with a lack of clarity on how this season’s flu respiratory virus could interact and have overlapping symptoms with COVID-19.
Most people will not self-quarantine until COVID-19 symptoms become severe. This testing lag can lead to rapid spread as the most infectious period for this highly contagious virus is two days before and after symptoms. Mass testing at point-of-care, such as walk-in, drive-through, and mobile testing facilities, can provide early detection and contain outbreaks. The low cost, safe INNOVA Rapid SARS-CoV-2 Antigen Test can screen asymptomatic individuals with 98.98% accuracy. The IMG test, which incorporates an advanced, nitrocellulose membrane, makes it one of the most advanced in the world. In vitro diagnostic (IVD), nasal, throat, and cheek swabs, are safely gathered and combined with a testing reagent. In as little as 20 minutes, a negative result provides peace of mind, while a positive result ensures one can quarantine and not spread the disease at school or a workplace.
With its encrypted blockchain security, the QDX HealthID™ Smartphone App tracks and reports test results privately. The app (available on iPhone and Android devices) collects a person’s name, email address, phone number, zip code, and test results. This easy-to-use digital “health passport” lets people share information only to those who need to know. A user’s authenticated status will be displayed with a green, yellow, or red badge. Its cloud-based technology, Auth0 integration, and capture of QR codes complies with HIPAA and HL7 requirements. The QDX HealthID™ Smartphone App will never share privacy data.
Not only can COVIDLytics™’ customizable set of rules quantify risk on an individual basis, but also the risk to a specific environment. Community profiles can be generated to let local, state, and country government officials better target interventions. Its real-time data and predictive analytics will impart improved public health decisions and outcomes.
Misinformation has real-world consequences. Already, many communities face crowded hospitals and cost pressures. The mass amounts of data, collected through widespread testing, can be shared for research purposes and better case tracking of potential disease outbreaks.
COVIDLytics™’ open architecture adapts to different protocols so its data can be combined with data already collected in any existing testing environment. This speeds the integration of testing and tracing data systems and reduces the burden to research teams when proprietary software will not replicate in other environments. The use of COVIDLytics™ can identify high-risk groups, then alert hospitals, nursing homes, and schools to redirect their limited supply chain resources. Data-driven protocols will highlight whom to test and with what frequency. These factors, combined with digitally-based contact tracing, can contain the spread of the SARS-CoV-2 virus.
(0)
(0)